ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,448Medicare Part D Prescriptions Filled, Including Refills

Rank: 410 out of 1107

$462K Total Retail Price of All Prescriptions

Rank: 413 out of 1107

395 Patients Receiving at Least One Drug in Part D
71%Patients 65 Years and Older
68% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kentucky
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 395 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

26% of this provider’s 395 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

1% of this provider’s 6,603 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kentucky
HYDROCODONE-ACETAMINOPHEN 389 310 S3 1 1
OMEPRAZOLE 290 199 2 4
SIMVASTATIN 280 196 3 5
BUMETANIDE 276 224 4 123
AMLODIPINE BESYLATE 213 174 5 6
ZOLPIDEM TARTRATE 212 202 6 22
LISINOPRIL 212 154 6 2
LEVOTHYROXINE SODIUM 191 142 8 3
LIDODERM 191 190 8 140
FLUTICASONE PROPIONATE 162 90 10 38
POTASSIUM CHLORIDE 155 111 11 14
MIRTAZAPINE 137 132 12 61
WARFARIN SODIUM 134 116 13 15
METOPROLOL TARTRATE 124 98 14 10
DONEPEZIL HCL 122 118 15 32
EXELON 112 109 16 103
POLYETHYLENE GLYCOL 3350 110 104 17 46
AMLODIPINE BESYLATE-BENAZEPRIL 107 59 18 77
LISINOPRIL-HYDROCHLOROTHIAZIDE 106 61 19 24
NAMENDA 104 93 20 42
GABAPENTIN 95 74 21 9
ROPINIROLE HCL 85 61 22 69
ALENDRONATE SODIUM 83 68 23 41
CITALOPRAM HBR 80 71 24 17
NAPROXEN 79 41 25 80
GLIPIZIDE 78 75 26 64
PRAVASTATIN SODIUM 77 53 27 12
METFORMIN HCL 75 44 28 8
SERTRALINE HCL 74 62 29 20
LACTULOSE 73 56 30 89
ATORVASTATIN CALCIUM 72 44 31 13
LYRICA 69 62 32 83
ESCITALOPRAM OXALATE 69 58 32 82
NYSTATIN 66 57 34 110
DIVALPROEX SODIUM 62 60 35 96
ATENOLOL 61 38 36 19
CYCLOBENZAPRINE HCL 60 22 R 37 56
QUETIAPINE FUMARATE 59 55 38 94
TRAMADOL HCL 58 53 39 26
CLONIDINE HCL 57 41 40 53
KLOR-CON M20 52 25 41 75
RISPERIDONE 50 50 42 79
TRAZODONE HCL 50 46 42 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 11, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.